To ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that Government will not be procuring any doses of Evusheld at this time, what evidence base was used to support this decision; and if he will make a statement.
The decision not to procure Evusheld at this present time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective, enables access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Department wrote to patient groups on 5 September 2022 with information on the decision and we intend to publish further details of the clinical advice received shortly.